MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Assessing a Video Based Approach at Measuring Parkinson’s Disease Severity – A Validation Study

    BP. Bridges (St. John's, Canada)

    Objective: To validate the Parkinson’s remote interactive monitoring system’s assessment of Parkinson’s disease compared to a clinical assessment completed by a movement disorder specialist. Background:…
  • 2024 International Congress

    A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

    Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

    Objective: To compare  efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…
  • 2024 International Congress

    Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up

    R. Hauser, V. Fung, T. Kimber, K. Klos, M. Facheris, A. Jeong, J. Jia, A. Spiegel, M. Soileau (Tampa, USA)

    Objective: Evaluate long-term safety and efficacy of foslevodopa/foscarbidopa (LDp/CDp) among people with advanced Parkinson’s disease (aPD). Background: As aPD progresses, erratic gastric emptying and pulsatile…
  • 2024 International Congress

    GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA-mutation

    O. Siemeling, S. Slingerland, S. V/d Zee, T. van Laar (Groningen, Netherlands)

    Objective: To study the potential disease-modifying properties of ambroxol in PD patients with a GBA1 mutation Background: The most common genetic risk factor for Parkinson’s…
  • 2024 International Congress

    Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study

    S. Putri, R. Fajar, E. Syafruddin (Gresik, Indonesia)

    Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…
  • 2024 International Congress

    Programming Adaptive Deep Brain Stimulation in the Clinic: Lessons from the ADAPT-PD Trial

    T. Herrington, M. Beudel, J. Ostrem, S. Little, L. Almeida, A. Ramirez-Zamora, A. Fasano, T. Hassell, K. Mitchell, E. Moro, M. Gostkowski, N. Sarangmat, S. Stanslaski, L. Tonder, Y. Tan, R. Summers, T. Goble, R. Raike, H. Bronte-Stewart (Boston, USA)

    Objective: To present data and lessons learned from the ADAPT-PD trial Background: Adaptive deep brain stimulation (aDBS) will require strategies for efficient and effective aDBS…
  • 2024 International Congress

    NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease

    M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Wuhan, China)

    Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…
  • 2024 International Congress

    24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease

    S. Thirunavukarasu, B. Ramanan, V. Varadharaj, TS. Suresh, KV. Verma, HAJ. Janardhanan, AUR. Ur (PUDUCHERRY, India)

    Objective: To assess tolerability, feasibility, safety and to assess outcome measures clinically as well as by serum levels over 24 hours, using the alternative maxillofacial…
  • 2024 International Congress

    Characterisation of the Pattern of Daily Motor Fluctuations in Patients with Parkinson’s Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study

    J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

    Objective: To characterise the pattern of daily motor fluctuations in Korean patients with Parkinson’s disease (PD) and early motor fluctuations. Background: Patients with PD may…
  • 2024 International Congress

    Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.

    S. Maytharakcheep, R. Bhidayasiri, O. Phokaewvarangkul (Bangkok, Thailand)

    Objective: To investigate the efficacy of botulinum toxin injection (BoNTA) in correcting eyebrow asymmetry in patients with hemifacial spasms (HFS). Background: HFS typically affects women…
  • « Previous Page
  • 1
  • …
  • 401
  • 402
  • 403
  • 404
  • 405
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley